JingJia Liu UDM
Dr. Ritu Lal, the CEO and Co-Founder of GEn1E Lifesciences Inc, is a seasoned professional with over 20 years of experience in the Biotech/Pharma industry. Her passion lies in bringing cost-effective and efficient healthcare products to patients. As a Senior Executive, Dr. Lal has led Preclinical and Clinical Development teams, taking compounds from Discovery to Regulatory Approval and filing over 15 Investigational New Drug Applications (IND) in various disease areas. Notably, two compounds she worked on received New Drug Application (NDA) approvals from the US FDA and Ministry of Health and Welfare, Japan. Dr. Lal holds a doctorate in Pharmaceutical Sciences and Pharmacology from the University of Maryland and a Master's degree in Pharmacology from the University of Arizona. Additionally, she earned a Master’s in Management from Stanford University’s MSx (Sloan) Program. GEn1E Lifesciences, under Dr. Lal's leadership, is a Clinical-stage biotech company with a unique AI platform. The company focuses on developing novel, next-generation immunomodulatory therapies for rare and inflammatory diseases with no effective treatments. GEn1E aims to supercharge the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities. The AI platform enables the development of purpose-built therapies, such as one for Acute Respiratory Distress Syndrome (ARDS), addressing its significant societal cost. GEn1E has a rich pipeline of 21+ novel immunomodulators and plans to accelerate two additional devastating diseases beyond their lead indication. The company's AI platform demonstrates exceptional pace and capital efficiency, showcasing progress in approximately two years with seed capital—a remarkable achievement compared to industry norms. With a mission to bring life-saving therapies to patients in need, GEn1E's team, with decades of experience in drug development and machine learning, positions the company as a significant player in the biotech industry.
